---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014355"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:04:58.846414+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment

## Summary
- 10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.
- GraftAssure RUO launch expected Q2 2024 at select US/EU transplant centers, broader rollout H2 2024.
- Bio-Rad gets exclusive global distribution rights outside US/Germany; option for IVD rights upon FDA clearance with second equity investment.
- Transplant monitoring market estimated over $1B with 157K annual transplants and 9.1% growth.
- Bio-Rad makes initial equity investment in Oncocyte; specific amount not disclosed.

## SEC filing metadata
- accession: 0001493152-24-014355
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014355
- JSON: https://secwatch.observer/filing/0001493152-24-014355.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014355.txt

## Key facts
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Bio-Rad Laboratories, Inc.
  - Effective: 2024-04-05
  source text: On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.